Phase II Trial of Neoadjuvant Recombinant Human Endostatin, Docetaxel and Epirubicin as First-line Therapy in Patients With Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 25 Mar 2016
At a glance
- Drugs Endostatin (Primary) ; Docetaxel; Epirubicin
- Indications Breast cancer
- Focus Therapeutic Use
- 21 May 2013 Primary endpoint 'Objective-clinical-response-rate' has been met.
- 07 Jun 2011 Results presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
- 22 Jan 2010 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.